Cargando…
The efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials
BACKGROUND: Dapagliflozin is a first-in-class oral sodium glucose co-transporter 2 (SGLT2) inhibitor. It is often used in combination with conventional anti-diabetic drugs such as metformin, glimepiride, and insulin in treating type 2 diabetes (T2D). It not only reduces glucose reabsorption in the k...
Autores principales: | Sun, Yu-nan, Zhou, Yi, Chen, Xi, Che, Wen-si, Leung, Siu-wai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833641/ https://www.ncbi.nlm.nih.gov/pubmed/24225054 http://dx.doi.org/10.1186/2046-4053-2-103 |
Ejemplares similares
-
The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials
por: Sun, Yu-nan, et al.
Publicado: (2014) -
Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis
por: Jiang, Yixuan, et al.
Publicado: (2021) -
Drug efficacy in treating stable angina pectoris: a protocol for network meta-analysis of randomised controlled trials
por: Jia, Yongliang, et al.
Publicado: (2014) -
Glycaemic control efficacy of oral antidiabetic drugs in treating type 2 diabetes: a protocol for network meta-analysis
por: Jia, Yongliang, et al.
Publicado: (2015) -
Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs
por: Luo, Menghui, et al.
Publicado: (2020)